Clinical trial · Interventional
Anatomical Resection of Liver MetAstases iN patIents With RAS-mutated Colorectal Cancer
NCT04678583CI-TRIAL-00077919ARMANIrecruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
the ARMANI trial will test the hypothesis, if an anatomic resection (AR) improves long-term outcome vs. a non-anatomical resection (NAR) in patients undergoing surgery for RAS-mutated colorectal liver metastasis (CRLM).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colorectal Liver Metastasis | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Resection of colorectal liver metastases | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- A - Anatomical resection
- description
- removal of the entire, tumor-bearing liver segment(s)
- interventionNames
- Procedure: Resection of colorectal liver metastases
- type
- ACTIVE_COMPARATOR
- label
- B - Non-anatomical resection
- description
- metastasectomy with a margin of healthy liver tissue irrespective of segmental borders
- interventionNames
- Procedure: Resection of colorectal liver metastases
Primary outcomes (1)
- measure
- Intrahepatic disease-free survival (iDFS)
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Colorectal cancer with RAS mutation (KRAS or NRAS) * Colorectal liver metastases (single or multiple) * Planned R0 resection of liver metastases (and primary tumor, if present) * Anatomical and non-anatomical liver resection technically feasible * Male and female patients, age ≥ 18 years * Written informed consent Exclusion Criteria: * Extrahepatic metastases * Planned staged liver resection (e.g. two-stage hepatectomy) * Diagnosis of another cancer \< 5 years prior to randomization Exceptions: curatively treated in situ cervical cancer, curatively resected non-melanoma skin cancer * Expected lack of compliance * Addiction or other illnesses which do not allow the person concerned to assess the nature and extent of the clinical trial and its possible consequences
References
Publications (0)
Data not yet available
No reference posted for this study.